Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tauri-Gum
- Development stage
- Preclinical
- Lead developer
- Tauriga Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Tauri-Gum** is Tauriga Sciences' proprietary cannabidiol-containing chewing-gum product platform. A proposed pharmaceutical-grade version was developed for chemotherapy-induced nausea and vomiting, with Tauriga engaging Clinical Strategies & Tactics for product-development, regulatory, clinical-strategy, commercialization, and funding planning activities intended to support a transition from a consumer CBD supplement to a potential FDA-regulated drug. No completed clinical trial, approved indication, or assigned INN for the pharmaceutical-grade candidate was identified.
- Brand names
- Tauri-Gum
- Other names
- Tauri Gum
Beyond the preview
Go deeper on Tauri-Gum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tauri-Gum.